Institutional Playbook Rewritten: Are Tech Giants Still the Safe Bets?

Morgan Stanley’s Q2 2025 13F analysis shows a clear rotation: institutions are adding to technology, industrials and communication services while trimming healthcare, financials and consumer staples. Hedge funds stand out for underweighting mega-cap tech but overweighting small-cap medicals. U.S. domestic funds now account for 81% of S&P 500 holdings, underscoring a home-bias that shapes sector flows.

What’s the big shift — and why does it matter?

Institutions increased exposure to technology by 1.9%, with industrials and communication services each up 0.6%. At the same time, healthcare fell 1.3%, and both financials and consumer staples dipped 0.7%. These moves signal renewed confidence in cyclicals and tech-led growth, while defensive and rate-sensitive sectors cooled off.

 

Hedge funds behaved differently from the broader market. They continued a long-running low allocation to large-cap tech but showed strong appetite for small-cap healthcare, revealing divergent tactical views inside active management.

Key Takeaways 

• Tech led inflows (+1.9%) while healthcare (-1.3%), financials (-0.7%), and staples (-0.7%) were net trimmed.

• Industrials and communication services each gained +0.6% in institutional allocation.

• Small-cap moves: small-cap tech +2.3%, small-cap consumer discretionary +0.9%; small-cap staples -0.9%, small-cap healthcare -0.8%.

• Hedge funds: persistent low allocation to large tech since 2017, but 28% of hedge fund small-cap assets are in small-cap medicals versus 10% weight in the Russell 2000.

• Geography: U.S. funds hold 81% of S&P 500 positions; EMEA 16%, APAC 3%.

• Regional nuances: North America supplies 86% of energy sector assets; real estate is most international at 22% foreign. APAC funds allocate 34% to U.S. tech, vs. LatAm at 26%.

• Top single-name shifts: Nvidia +7.4%, Microsoft +7.1%, Apple +5.8% among hedge fund active adds; Enphase +7.7% led overall increases. FICO -6.2% and Tapestry -4.9% were largest cuts.

(Analysis covers Top 100 funds and Top 100 hedge funds; 13F data reflect positions as of June 30 and exclude derivatives and short positions.)

Who’s buying — and who’s being sold?

Hedge funds and institutional managers are not acting in lockstep. Large institutions boosted exposure to secular growth and industrial recovery names, while other active managers rotated into small-cap, high-beta opportunities—especially biotech and small tech. Meanwhile, defensive names and select financials were trimmed, suggesting a preference for growth and cyclical upside over recession hedges.

 

Top active bets spotlight concentration: Nvidia, Microsoft and Apple head the list of hedge fund increases, revealing continued faith in platform and AI-related leaders despite hedge funds’ broader low-tech posture.

Small caps: opportunity or risk — which is it?

Small-cap allocations are more aggressive and more differentiated. Tech and discretionary small caps saw meaningful inflows, while staples and healthcare small caps experienced outsized selling. Hedge funds’ overweight in small-cap medicals (driven by biotechs) implies a search for asymmetric returns, but it raises concentration risk if biotech catalysts disappoint.

Investors should distinguish between durable small-cap winners and speculative plays; the 13F snapshot shows where professional liquidity currently targets potential outsized growth.

Regional tilt — who’s leading the global chorus?

U.S. domestic funds dominate S&P 500 ownership at 81%, reinforcing home bias in institutional portfolios. EMEA funds have slightly higher relative exposure to tech than U.S. peers, while APAC managers hold the largest share of U.S. tech overall (34%). LatAm funds favor materials, financials and healthcare over tech.

 

Sector geography matters: energy is overwhelmingly North American, while real estate sees the most international capital, hinting at where cross-border investors find value or familiarity.

Longer trends — are we seeing lasting change?

The report confirms structural patterns. Since 2010, technology and discretionary exposure has been relatively underweighted by many investors because mega-caps already dominate indices. Conversely, industrials and healthcare have sustained overweight positions. Hedge funds accentuate these structural tilts: stronger overweights in industrials/healthcare and persistent underweights in mega-tech.

 

This suggests current moves are partly tactical overlay on top of long-term positioning rather than wholesale regime change.

What this means for investors — practical signals

First, look inside sectors: tech’s headline inflow masks internal shifts—mega-caps still dominate, while smaller tech names are the tactical focus. Second, watch small-cap healthcare: hedge fund concentration signals both opportunity and volatility. Third, consider regional flows when building cross-border exposure—U.S. domestic dominance can compress returns if international flows reverse.

 

Importantly, 13F data are lagged to June 30; holdings may have materially shifted since. Use the 13F snapshot as a directional read, not a trade instruction.

How to read the numbers — methodology matters

Morgan Stanley’s analysis aggregates Top 100 institutional and Top 100 hedge fund 13F filings, excluding derivatives and short exposures. The percentages reported reflect active weight changes versus the S&P 500 or Russell 2000 benchmarks as described. This clarifies the scope and limits of inference from the dataset.

 

Q2’s 13F picture shows selective conviction: institutions are betting on technology, industrials and communications, while trimming defensive and rate-sensitive sectors. Hedge funds are playing a different hand—underweighting mega-tech but doubling down on small-cap medicals. For investors, the lesson is simple: focus on internal sector structure, monitor small-cap biotech concentration, and respect the lag in 13F data when acting.